Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
复制标题
DOI：
10.1186/s12879-021-06164-x
复制
发表时间：
2021-05-27
影响因子：
3.7
通讯作者：
Kudo K
中科院分区：
文献类型：
--
作者：
Manabe T;Kambayashi D;Akatsu H;Kudo K
法匹拉韦在治疗COVID-19患者方面具有很高的效用。然而，关于favipiravir对COVID-19患者的疗效和安全性的研究有限。我们对已发表的报告favipiravir对COVID-19疗效的研究进行了系统回顾。两名研究者独立检索了PubMed、Cochrane系统评价数据库、MedRxiv和ClinicalTrials.gov（创建至2020年9月），以确定符合条件的研究。进行了一项荟萃分析，以衡量病毒清除和临床改善作为主要结果。在11项符合条件的研究中，有5项纳入了比较组。与比较组相比，favipiravir组在治疗开始后第7天表现出明显更好的病毒清除率（优势比[OR] = 2.49, 95%可信区间[CI] = 1.19-5.22），而在第14天没有差异（OR = 2.19, 95% CI = 0.69-6.95）。虽然favipiravir组在第7天和第14天的临床改善明显更好，但第14天的改善（OR = 3.03, 95% CI = 1.17-7.80）优于第7天（OR = 1.60, 95% CI = 1.03-2.49）。favipiravir组患者在第7天和第14天的病毒清除率分别为65.42%和88.9%，而比较组分别为43.42%和78.79%。favipiravir组患者在第7天和第14天临床改善的估计比例分别为54.33%和84.63%，而比较药组分别为34.40%和65.77%。Favipiravir在7天内诱导病毒清除，并在14天内促进临床改善。结果表明，favipiravir具有很强的治疗COVID-19的可能性，特别是对轻中度疾病患者。其他设计良好的研究，包括对治疗剂量和持续时间的检查，对于得出明确的结论至关重要。在线版本包含补充材料，可在10.1186/s12879-021-06164-x获得。
Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited. We conducted a systematic review of published studies reporting the efficacy of favipiravir against COVID-19. Two investigators independently searched PubMed, the Cochrane Database of Systematic Reviews, MedRxiv, and ClinicalTrials.gov (inception to September 2020) to identify eligible studies. A meta-analysis was performed to measure viral clearance and clinical improvement as the primary outcomes. Among 11 eligible studies, 5 included a comparator group. Comparing to the comparator group, the favipiravir group exhibited significantly better viral clearance on day 7 after the initiation of treatment (odds ratio [OR] = 2.49, 95% confidence interval [CI] = 1.19–5.22), whereas no difference was noted on day 14 (OR = 2.19, 95% CI = 0.69–6.95). Although clinical improvement was significantly better in the favipiravir group on both days 7 and 14, the improvement was better on day 14 (OR = 3.03, 95% CI = 1.17–7.80) than on day 7 (OR = 1.60, 95% CI = 1.03–2.49). The estimated proportions of patients with viral clearance in the favipiravir arm on days 7 and 14 were 65.42 and 88.9%, respectively, versus 43.42 and 78.79%, respectively, in the comparator group. The estimated proportions of patients with clinical improvement on days 7 and 14 in the favipiravir group were 54.33 and 84.63%, respectively, compared with 34.40 and 65.77%, respectively, in the comparator group. Favipiravir induces viral clearance by 7 days and contributes to clinical improvement within 14 days. The results indicated that favipiravir has strong possibility for treating COVID-19, especially in patients with mild-to-moderate illness. Additional well-designed studies, including examinations of the dose and duration of treatment, are crucial for reaching definitive conclusions. The online version contains supplementary material available at 10.1186/s12879-021-06164-x.
登录
查看更多内容
DOI：
10.2183/pjab.93.027
发表时间：
2017
期刊：
Proceedings of the Japan Academy. Series B, Physical and biological sciences
影响因子：
--
作者：
Furuta Y;Komeno T;Nakamura T
通讯作者：
Nakamura T
影响因子：
1.8
作者：
Agresti, A;Coull, BA
通讯作者：
Coull, BA
影响因子：
4.1
作者：
Klimczak A
通讯作者：
Klimczak A
影响因子：
105.7
作者：
Higgins, JPT;Thompson, SG;Altman, DG
通讯作者：
Altman, DG
影响因子：
39.2
作者：
Moher, David;Liberati, Alessandro;Altman, Douglas G.
通讯作者：
Altman, Douglas G.